Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model
Open Access
- 1 August 2014
- journal article
- Published by Elsevier BV in Behavioural Brain Research
- Vol. 269, 81-86
- https://doi.org/10.1016/j.bbr.2014.04.028
Abstract
No abstract availableKeywords
Funding Information
- Janssen Research & Development
This publication has 28 references indexed in Scilit:
- α2C-adrenoceptor modulators: a patent reviewExpert Opinion on Therapeutic Patents, 2011
- Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's diseaseBrain Research, 2011
- The MPTP marmoset model of Parkinsonism: a multi-purpose non-human primate model for neurodegenerative diseasesDrug Discovery Today, 2010
- From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's diseasePharmacology & Therapeutics, 2010
- Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteersJournal of Psychopharmacology, 2006
- Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α2‐Adrenoceptor AntagonistCNS Drug Reviews, 2005
- Parkinson's Disease: Mechanisms and ModelsNeuron, 2003
- α2-Adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the α2A-adrenoceptor subtypeNeuropharmacology, 2003
- Effects of low doses of cholinesterase inhibitors on behavioral performance of robot-tested marmosetsPharmacology Biochemistry and Behavior, 1995
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991